Trinity Biotech
TRIB
34 hedge funds and large institutions have $20.3M invested in Trinity Biotech in 2021 Q1 according to their latest regulatory filings, with 11 funds opening new positions, 2 increasing their positions, 11 reducing their positions, and 3 closing their positions.
267% more first-time investments, than exits
New positions opened: 11 | Existing positions closed: 3
31% more funds holding
Funds holding: 26 → 34 (+8)
13% more call options, than puts
Call options by funds: $602K | Put options by funds: $533K
0.13% less ownership
Funds ownership: 1.42% → 1.29% (-0.13%)
10% less capital invested
Capital invested by funds: $22.6M → $20.3M (-$2.29M)
82% less repeat investments, than reductions
Existing positions increased: 2 | Existing positions reduced: 11
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Acadian Asset Management
Boston,
Massachusetts
|
+$620K |
| 2 |
Marshall Wace
London,
United Kingdom
|
+$436K |
| 3 |
Squarepoint
New York
|
+$175K |
| 4 |
State of New Jersey Common Pension Fund D
Trenton,
New Jersey
|
+$130K |
| 5 |
LPL Financial
San Diego,
California
|
+$106K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SCM
Stonehill Capital Management
New York
|
-$2.42M |
| 2 |
Morgan Stanley
New York
|
-$516K |
| 3 |
Two Sigma Investments
New York
|
-$428K |
| 4 |
Renaissance Technologies
New York
|
-$297K |
| 5 |
HAIM
Hunter Associates Investment Management
Pittsburgh,
Pennsylvania
|
-$186K |
TRIB Hedge Fund Activity: Q1 2021 in Review
34 of the 5,695 institutional investors tracked by Wall St. Rank reported a position in Trinity Biotech (TRIB) for Q1 2021, worth a combined $20.3M — down 10% from $22.6M a quarter earlier.
Buyers outnumbered sellers: 11 funds opened new TRIB positions and 3 closed out — a net gain of 8 holders — while 2 added to existing stakes and 11 trimmed.
The largest buyer was Acadian Asset Management, adding an estimated $620K. The largest seller was Stonehill Capital Management, cutting an estimated $2.42M.
- 34 institutional investors held Trinity Biotech (TRIB) as of Q1 2021, up from 26 in Q4 2020.
- Funds reported $20.3M of Trinity Biotech stock for Q1 2021, down 10% quarter-over-quarter.
- 11 funds opened new Trinity Biotech positions in Q1 2021 and 3 closed out, a net change of +8 holders.
- The largest Trinity Biotech buyer in Q1 2021 was Acadian Asset Management, an estimated $620K added.
- The largest Trinity Biotech seller in Q1 2021 was Stonehill Capital Management, an estimated $2.42M sold.
Based on aggregated 13F filings for Q1 2021.